<span item_type="fundamental" item_id="ef80cb0477cb99dc5fee08a67912fc96" counter_id="ST/US/FTIIW" env="prod"></span><span item_type="announcement" item_id="518295552970986753" env="prod"></span><p>EPS: As of FY2025 Q1, the actual value is USD -0.74.</p><p>EBIT: As of FY2025 Q1, the actual value is USD -254.01 K.</p><p></p><h3>Segment Revenue</h3><ul><li>The company has not generated any operating revenues as of March 31, 2025, and will not generate any until after the completion of its initial Business Combination.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1889450/000164117225011790/form10-q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Net loss for the three months ended March 31, 2025, was - $289,673, compared to a net income of $129,577 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1889450/000164117225011790/form10-q.htm"></span></li><li>Total expenses for the three months ended March 31, 2025, were $453,835, compared to $310,934 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1889450/000164117225011790/form10-q.htm"></span></li><li>Interest income for the three months ended March 31, 2025, was $199,826, compared to $536,343 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1889450/000164117225011790/form10-q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used in operating activities for the three months ended March 31, 2025, was - $453,155, compared to - $282,082 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1889450/000164117225011790/form10-q.htm"></span></li><li>Net cash provided by investing activities for the three months ended March 31, 2025, was $17,626,596, compared to $36,273,240 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1889450/000164117225011790/form10-q.htm"></span></li><li>Net cash used in financing activities for the three months ended March 31, 2025, was - $17,099,629, compared to - $36,008,323 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1889450/000164117225011790/form10-q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>The company has a working capital deficit of $5,290,544 as of March 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1889450/000164117225011790/form10-q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company is focused on completing its initial Business Combination with Longevity Biomedical, Inc. The consummation of this proposed combination is subject to certain conditions as described in the Merger Agreement.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1889450/000164117225011790/form10-q.htm"></span></li><li><strong>Non-Core Business</strong>: The company has entered into a Subscription Agreement with an investor for a private placement of 1,000,000 shares of Class A Common Stock at $5.00 per share, contingent upon the consummation of the Business Combination with Longevity.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1889450/000164117225011790/form10-q.htm"></span></li><li><strong>Priority</strong>: The company has until August 18, 2025, to complete a Business Combination, failing which it will undergo mandatory liquidation and dissolution.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1889450/000164117225011790/form10-q.htm"></span></li></ul>

FUTURETECH II ACQUISITION CORP C/WTS 18/08/2028 (TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD -0.74